HZHong-Mei Zhang

Hong-Mei Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hong-Mei Zhang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Dong-Sheng Li

    Department of Oncology, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Jining, Shandong 272011, China

    1 shared publication
  • Hong-Zhi Sun

    Department of Oncology, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Jining, Shandong 272011, China

    1 shared publication
  • Qiang Li

    Department of Oncology, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Jining, Shandong 272011, China

    1 shared publication
  • Tian-Yi Wang

    Department of Immunology, Laiwu Municipal Center for Disease Control & Prevention, Laiwu 271100, China

    1 shared publication
  • Yin-Peng Huang

    Department of Oncology, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Jining, Shandong 272011, China

    1 shared publication
  • Ying Liu

    Department of Immunology, Laiwu Municipal Center for Disease Control & Prevention, Laiwu 271100, China

    1 shared publication

Latest Publications

  • Retracted
    Open Access

    Influence ofDPYDGenetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis

    by Qiang Li, Ying Liu, Hong-Mei Zhang, Yin-Peng Huang, Tian-Yi Wang, Dong-Sheng Li, Hong-Zhi Sun

    Our meta-analysis aggregated existing results from relevant studies to comprehensively investigate the correlations between genetic polymorphisms in dihydropyrimidine dehydrogenase (DPYD) gene and 5-fluorouracil (5-FU) toxicities in patients with colorectal cancer (CRC). The MEDLINE (1966∼2013), the Cochrane Library Database (Issue 12, 2013), EMBASE (1980∼2013), CINAHL (1982∼2013), Web of Science (1945∼2013), and the Chinese Biomedical Database (CBM) (1982∼2013) were searched without language restrictions. Meta-analyses were conducted with the use of STATA software (Version 12.0, Stata Corporation, College Station, TX, USA). Seven clinical cohort studies with a total of 946 CRC patients met our inclusion criteria, and NOS scores of each of the included studies were ≥5. Our findings showed thatDPYDgenetic polymorphisms were significantly correlated with high incidences of 5-FU-related toxicity in CRC patients. SNP-stratified analysis indicated that there were remarkable connections of IVS14+1G>A, 464T>A, and 2194G>A polymorphisms with the incidence of marrow suppression in CRC patients receiving 5-FU chemotherapy. Furthermore, we found that IVS14+1G>A, 496A>G, and 2194G>A polymorphisms were correlated with the incidence of gastrointestinal reaction. Ethnicity-stratified analysis also revealed thatDPYDgenetic polymorphisms might contribute to the development of marrow suppression and gastrointestinal reaction among Asians, but not among Caucasians. The present meta-analysis suggests thatDPYDgenetic polymorphisms may be correlated with the incidence of 5-FU-related toxicity in CRC patients.